Cargando…

Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study

SIMPLE SUMMARY: Growing evidence has reported the role of sorafenib in hepatocellular carcinoma (HCC) patients with liver transplantation (LT). However, the clinical impact of lenvatinib in this population is limited. Our study enrolled 10 HCC patients who received lenvatinib after LT in our institu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yen-Yang, Chen, Chao-Long, Lin, Chih-Che, Wang, Chih-Chi, Liu, Yueh-Wei, Li, Wei-Feng, Chen, Yen-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469287/ https://www.ncbi.nlm.nih.gov/pubmed/34572811 http://dx.doi.org/10.3390/cancers13184584

Ejemplares similares

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Bang, Kyunghye, et al.
Publicado: (2022)

Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center
por: Liu, Yueh-Wei, et al.
Publicado: (2020)

Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma
por: Yen, Yi-Hao, et al.
Publicado: (2023)

Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam
por: Nguyen-Dinh, Song-Huy, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria
por: Guo, De-Zhen, et al.
Publicado: (2022)

Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma
por: Tsai, Ming Chao, et al.
Publicado: (2022)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Comparative study of the safety and efficacy of SMOFlipid vs non SMOFlipid as TPN for liver transplantation
por: Wu, Mei-Yun, et al.
Publicado: (2021)

Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology
por: Yen, Yi-Hao, et al.
Publicado: (2023)

Characteristics of Psychosocial Factors in Liver Transplantation Candidates with Alcoholic Liver Disease before Transplantation: A Retrospective Study in a Single Center in Taiwan
por: Chen, Yu-Ming, et al.
Publicado: (2020)

Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment
por: Chan, Kun-Ming, et al.
Publicado: (2023)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
por: Perng, Pang-Shuo, et al.
Publicado: (2022)

Incidence and Risk Factors of Alcohol Relapse after Liver Transplantation: Analysis of Pre-Transplant Abstinence and Psychosocial Features
por: Yu, Tien-Wei, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients
por: Yen, Yi-Hao, et al.
Publicado: (2023)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy
por: Tsai, Ming-Chao, et al.
Publicado: (2021)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
por: Okusaka, Takuji, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma
por: Liu, Yulong, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
por: Zhu, Yun, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
por: Wang, Dong-Xu, et al.
Publicado: (2020)

Impacts of Pretransplant Infections on Clinical Outcomes of Patients with Acute-On-Chronic Liver Failure Who Received Living-Donor Liver Transplantation
por: Lin, Kuo-Hua, et al.
Publicado: (2013)

Resection of an intra-operative ruptured hepatocellular carcinoma with continuous pringle maneuver and in situ hypothermic perfusion through the inferior mesenteric vein - a case report
por: Lin, Yueh-Ming, et al.
Publicado: (2013)

Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma
por: Yang, Shih-Yu, et al.
Publicado: (2021)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West
por: Yen, Yi-Hao, et al.
Publicado: (2020)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

The Perioperatively Altered Neutrophil-to-Lymphocyte Ratio Associates with Impaired DNA Damage Response in Liver Transplantation Recipients with Hepatocellular Carcinoma
por: Chen, Kuang-Den, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rdof7epof7sv8ou7mcd74pdml4